Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 4846 Download: 252 Web of Science: 11 Crossref: 14

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2404 Download: 57 Web of Science: 1 Crossref: 2

Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed

Clin Mol Hepatol. 2021;27(3):486-498. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2020.0162

View: 5556 Download: 253 Web of Science: 20 Crossref: 22

Viewed By 5661	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4906	MAFLD: How is it different from NAFLD?
Viewed By 4682	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3797	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3778	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Author :

Author index